Cha Biotech announced Thursday the transfer of 8.95 million shares of Cha Vaccine Institute, valued at 23.8 billion won ($15.8 million USD), to Solux, AriBio Investment Purpose No. 13, and other investors.
This transaction will reduce Cha Biotech’s ownership in the Kosdaq-listed Cha Vaccine Institute to 1.34 million shares, representing a 4.99 percent stake. This signifies a strategic shift away from management control, while maintaining a minority interest to foster potential future collaborations.
The capital generated from this sale will be strategically reinvested into bolstering key growth sectors, including cell and gene therapy (CGT), CDMO expansion, and the development of AI-powered digital healthcare solutions.
This move is part of a larger strategic portfolio realignment, designed to focus resources on high-potential bio-health segments. Previously, the Cha Group divested its entire stake in Solidus Investment, a bio-health venture capital firm, to JW Holdings.
While Cha Vaccine Institute specializes in the development of next-generation vaccines, Cha Biotech stated that this area offers limited synergistic opportunities with CGT, which has become the company’s primary engine for growth.
Cha Biotech intends to further streamline its business portfolio, concentrating on CGT, AI-driven healthcare, and broader life sciences initiatives to enhance its global competitive edge in the biotechnology industry.
stlee0329
